菌感染淄博_培训课件.ppt

* * * * * * Diagn Microbiol Infect Dis. 2005 Aug;52(4):317-22. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Kiffer CR， Sampaio JL， Sinto S， Oplustil CP， Koga PC， Arruda AC， Turner PJ， Mendes C. Source Advisory Group on Antimicrobials and Clinical Microbiology， Fleury Institute， 04344-070 Jabaquara-Sao Paulo-SP， Brazil. carlos.kiffer@.br Abstract Meropenem and imipenem are often the drugs of choice for the treatment of infections due to multidrug-resistant Acinetobacter baumannii. The present study aimed at evaluating the interaction between meropenem and sulbactam through microdilution and checkerboard methods against 48 clinical isolates of A. baumannii collected from Brazilian hospitals. All the isolates presented elevated minimum inhibitory concentration (or=2 microg/mL) to either meropenem or sulbactam. The checkerboard method with the combination of meropenem and sulbactam demonstrated 29.2% (14/48) synergism， 47.9% (23/48) partial synergism， 10.5% (5/48) additive， 6.2% (3/48) indifference， and 6.2% (3/48) antagonism (SigmaFIC(min)=0.09 and SigmaFIC(max)=8). Thus， combinations of meropenem and sulbactam may show synergism or partial synergism for most A. baumannii isolates. Further studies may help identify treatment options for patients with infections caused by these organisms， particularly with this combination， where both drugs have time-dependent activities and might be suitable for therapy optimization studies. * * Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients Wang Liang， et al BMC Infectious Diseases 2011， 11:109 A combination of meropenem (16 μg/mL) with minocycline (0.5×MIC， 4or 2 μg/mL) was synergitic to all test isolates， but neither showed bactericidal activity alone. combinations of colistin at 0.5×MIC (0.25 or 0.125 μg/mL) with each of the above were synergistic and shown bacte